Pages that link to "Q33344274"
Jump to navigation
Jump to search
The following pages link to Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. (Q33344274):
Displaying 10 items.
- Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. (Q33380148) (← links)
- Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia (Q33881750) (← links)
- P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808 (Q34124919) (← links)
- Biology and clinical impact of human natural killer cells (Q35190471) (← links)
- Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT. (Q35850723) (← links)
- Potential role of natural killer cell receptor-expressing cells in immunotherapy for leukemia (Q36045773) (← links)
- NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy (Q36484325) (← links)
- Human natural killer cells (Q36787596) (← links)
- Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity (Q36955475) (← links)
- Immune Escape after Hematopoietic Stem Cell Transplantation (HSCT): From Mechanisms to Novel Therapies (Q92282719) (← links)